WBC
KERX

Westpac Banking Corp’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Westpac Banking Corp’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-54,010
Closed -$390K – 867
2017
Q2 		$390K Buy
+54,010
New +$337K 0.01% 755

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Westpac Banking Corp's KERX Position: Q3 2017 in Review

Westpac Banking Corp sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2017, closing a stake of 54,010 shares — an estimated $390K sold.

Westpac Banking Corp first reported a position in KERX in Q2 2017 and held it in 1 quarter. The position peaked at $390K in Q2 2017. 132 funds tracked by Wall St. Rank hold KERX as of Q3 2017.

  • Westpac Banking Corp reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Westpac Banking Corp sold 54,010 Keryx Biopharmaceuticals Inc shares in Q3 2017, an estimated $390K.
  • Westpac Banking Corp first reported a position in Keryx Biopharmaceuticals Inc in Q2 2017 and held it in 1 quarter.
  • Westpac Banking Corp's Keryx Biopharmaceuticals Inc position peaked at $390K in Q2 2017.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2017.

Based on Westpac Banking Corp's 13F filing for Q3 2017, filed 30 Oct 2017.